Iopromide reduces HEK 293 MTT viability
Cell-based study · HEK 293 human embryonic kidney cell line; DMEM with 10% fetal bovine serum [1]
MTT signal declined with increasing concentration and longer exposure relative to untreated cells. Reported IC50 values are assay endpoints, not treatment doses.
| Endpoint | Reported result | Reference |
|---|---|---|
| MTT viability relative to untreated control | Reported IC50 24 h: 187±3.45 mgI/ml; 48 h: 53.10±1.87 mgI/ml | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 25, 50, 100 and 200 mgI/ml
- Exposure duration
- 24 or 48 h
- Method
- Ultravist exposure followed by MTT assay; untreated control normalized to 100%
- Reported limits
- Ultravist stock concentration and excipient-matched/osmolality-matched control are not described. IC50 fitting and the uncertainty definition for the reported IC50 values are not specified.
Methods and source locations
Compound reported in the paper: Iopromide; Compound label in the paper: Ultravist commercial iopromide formulation
High-concentration cell-culture effects of the tested formulation; no inference of human dosing or Adooq lot performance.
Methods: Reagents and chemicals; Morphology and cell viability; Statistical analysis. Results first paragraph and Figure 1A–B.
MTT viability relative to untreated control: MTT absorbance at 570 nm; Figure 1 caption: mean±SE, n=3; general statistics section: at least three independent experiments, mean±SD. IC50 ± definition unresolved. — Results: Iopromide significantly inhibited HEK 293 cell proliferation; Figure 1A–B and caption; Methods: Statistical analysis.